Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Fig. 4

Spider plot. Tumor burden kinetics in patients with advanced non–small-cell lung cancer treated with PD-1/PD-L1 therapy. Baseline tumor measurements are standardized to zero. Tumor burden was measured as sum of longest diameters of target lesions compared with baseline. Percent change in target lesion tumor burden from baseline over time. Only includes patients with baseline target lesion and one or more post baseline target lesion assessments with no missing value (n = 16). Gray zone denote more than 30% decrease. Solid line and dotted line indicate on treatment and off treatment respectively. Star show occurrence of new lesion

Back to article page